Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00015060
DRKS00015060
Active, not recruiting
Not Applicable

Pre-screening for sensitivity to investigational anti-cancer drugs in patients with cancer

Oncology Venture ApS0 sites13 target enrollmentJuly 10, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsadvanced cancer (all indications)

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
advanced cancer (all indications)
Sponsor
Oncology Venture ApS
Enrollment
13
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 10, 2018
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Oncology Venture ApS

Eligibility Criteria

Inclusion Criteria

  • •i. Histological or cytological documented locally advanced or metastatic solid tumor relapsed on 1 or more different prior therapies
  • •ii. Age \= 18 years
  • •iii. Written informed consent
  • •iv. Life expectancy \= 6 months
  • •v. ECOG Performance status \= 1
  • •vi. FFPE tumor tissue available

Exclusion Criteria

  • •i. Other primary malignancy within the last 5 years prior to enrolment, except for adequately treated squamous cell carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
  • •ii. Evidence of any other disease or psychological dysfunction giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect patients understanding of the information, compliance with study routines, or place the patient at high risk from treatment related complications.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Anatomic variables to affect the difficult CEBDiseases of the musculo-skeletal system and connective tissue
KCT0000474The Catholic University of Korea, Seoul St. Mary's Hospital100
Not yet recruiting
Not Applicable
RBS to be used for diagnosing diabetics and Pre-diabetics in normal OPD population and any complications present if any.
CTRI/2022/10/046464none
Completed
Not Applicable
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer
JPRN-UMIN000010429EPS Corporation100
Not yet recruiting
Phase 4
Development of an early screening instrument for Autism Spectrum Disorder.Health Condition 1: F840- Autistic disorder
CTRI/2022/04/041686C A Ashitha Sreelakshmi
Recruiting
Not Applicable
Development of a screening procedure on the need for early pedeatric aids in early detection examaniatioF32F43.2Depressive episodeAdjustment disorders
DRKS00004949IVERSITAETSKLINIKUM FREIBURGKlinik I für Allg. PädiatrieZentrum für Kinder- und Jugendmedizin500